A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry

Simple item page
dc.contributor.authorFatoş ÖNEN
dc.contributor.authorGerçek CAN
dc.contributor.authorSedat ÇAPAR
dc.contributor.authorEdiz DALKILIÇ
dc.contributor.authorYavuz PEHLİVAN
dc.contributor.authorSoner ŞENEL
dc.contributor.authorServet AKAR
dc.contributor.authorSüleyman KOCA
dc.contributor.authorAbdurrahman TUFAN
dc.contributor.authorAyten YAZICI
dc.contributor.authorSema YİLMAZ
dc.contributor.authorNevsun İNANÇ
dc.contributor.authorİsmail SARI
dc.contributor.authorAHMET MERİH BİRLİK
dc.contributor.authorDilek SOLMAZ
dc.contributor.authorAyşe CEFLE
dc.contributor.authorMehmet Akif ÖZTÜRK
dc.contributor.authorServet YOLBAŞ
dc.contributor.authorNiels Steen KROGH
dc.contributor.authorNeslihan YILMAZ
dc.contributor.authorŞükran ERTEN
dc.contributor.authorCemal BES
dc.contributor.authorÖzgül SOYSAL GÜNDÜZ
dc.contributor.authorBerna GÖKER
dc.contributor.authorSeminur HAZNEDAROĞLU
dc.contributor.authorŞule YAVUZ
dc.contributor.authorMuhammet SEYİTHANOĞLU
dc.contributor.authorFatih YILDIZ
dc.contributor.authorHaner DİRESKENELİ
dc.contributor.authorNurullah AKKOÇ
dc.date.accessioned2024-07-24T09:08:39Z
dc.date.available2024-07-24T09:08:39Z
dc.date.issued2022
dc.description.abstractObjective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018. Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treatments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens. Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a conventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31. Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.
dc.identifier.DOI-ID10.5152/eurjrheum.2022.21060
dc.identifier.issn2147-9720
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/21485
dc.language.isoeng
dc.titleA real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry
dc.typeAraştırma Makalesi

Files

Collections

TR-Dizin Koleksiyonu